outlook baxter expect may
may baxter host second analyst day sinc almeida took
ceo role januari sinc he transform baxter
compani grow organ sale expand ebita margin
deliv annual ep growth improv
annual success turnaround two plu year
natur question whether there still go think answer
ye may analyst day expect manag refresh
target lay bullish set goal regist well street
estim expect target baxter rais top-lin
growth grow oper incom mid-teen impli
ebita vs sustain strong gener
vs set goal achiev top quartil total
sharehold return would requir baxter gener annual
return expect target dont includ addit
 assum conserv capit alloc strategi mean noth
beyond use share repurchas off-set dilut buyer
analyst day see upsid long-term street
estim reiter ow rate price target
pathway organ sale growth expect baxter
target organ sale growth
exclud addit benefit baxter current grow
vs weight averag market growth rate wamgr
shift growth vs wagmgr baxter transit
portfolio toward higher growth area new product launch play major
role drive futur growth across renal kaguya theranova prismax
new sealant gener inject advanc surgeri pharma
expect baxter guid mid-teen oper growth
impli ebita margin vs street baxter
gener ebita margin forecast reach
put well track meet exceed previou guidanc
expect gross margin grow new
product launch sg target declin
manag zero-bas budget alreadi gener
save believ still anoth round cut go
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
bottom-lin impli ep north base-cas
capit deploy scenario street us
estim would impli ep growth next year
combin dividend yield steadi multipl would gener top-
quartil total sharehold return per year base case scenario
assum annual share repurchas current assum
model starter street forecast revenu trajectori organ
baxter go forward vs exit rate expect manag guid
second street assum modest gross margin sg
improv go forward recent discuss manag lead us
believ still signific improv made front
that without use meaning capit deploy stand today
baxter net debt leav edward intuit surgic three
med-tech compani havent yet deploy balanc sheet assum
baxter spend share repurchas grow
compound-annual-growth-rate without signific
 capit restructur theyll end close cash
balanc sheet mean expect baxter actual end
much cash highlight street arent factor materi
capit deploy estim
accret prefer use cash absent baxter turn
larger opportunist share repurchas believ almeida hold
rigor approach evalu time may slow pace deal
activ baxter opt true valu creation rather immedi ep accret
natur favor smaller deal size rather larger size
transform acquisit baxter deal need exceed
compani wacc accret year fall
within exist wheelhous capabl baxter unlik enter white
space expect medic manag renal prioriti
expans well high-growth potenti busi like advanc
surgeri baxter ad recothrom prevaleak
go forward expect baxter continu prune unprofit contract
similar exit manag appli rigor
calcul product contract entir geographi
busi unit well
tabl lay expect baxter analyst meet
manag guidanc sinc spin baxalta expect
year meet assumpt reflect latest model
state expect baxter rais top-lin growth
grow oper incom mid-teen impli ebita vs
sustain strong gener vs
set goal achiev top quartil total sharehold return would
requir baxter gener annual return expect
target dont includ addit assum conserv
capit alloc strategi mean noth beyond use share repurchas
compani report morgan estim
aggress capit alloc scenario think baxter
gener ep neighborhood hit lrp target
scenario baxter could use cash debt repurchas
addit share assum model
still manag gross debt/ebitda net
debt/ebitda howev practic scenario less like baxter
approach like balanc smart pair share
repurchas messag capac deploy balanc sheet
signific potenti upsid estim rather almost everi scenario
oppos let cash accumul street model includ
buyer head analyst day baxter current
trade ev/ebitda ep estim
compar large-cap med-tech peer ev/ebitda
ep assum baxter trade par peer ev/ebitda
appropri view given lower leverag vs peer translat
stock price upsid baxter abl track closer
think lrp target fall continu exceed seemingli conserv
street estim upsid signific
turn back analyst day want flag number baxter
pipelin product expect see highlight analyst meet
start renal periton dialysi pd baxter launch kaguya
autom periton dialysi system japan market
patient initi dialysi annual nearli half treat in-cent leav
signific market opportun kaguya includ sharesourc remot
patient manag similar amia us start launch earlier
year
hemodialysi hd expect theranova receiv signific
amount attent potenti out-year driver growth first introduc
analyst meet devic approv countri
europ combin benefit hemodiafiltr innov membran
self-contain water system doesnt requir special staff ultrapur
fluid use baxter meet next year hope secur
differenti reimburs code theranova
occur devic potenti signific revenu contributor current
dialyz reimburs fall bundl dialysi payment would allow
modest uptak center valu eas use lack special
water system add-on differenti reimburs theranova
would make much financi sens center
acut therapi baxter hope enter sepsi market
prismaflex system outsid us baxter build clinic data
prismaflex system sepsi use oxiri blood purif set hope use
support indic us sepsi condit affect
critic ill patient icu repres sever hundr million dollar
new market opportun baxter gener conduct trial sepsi
extrem expens usual difficult gener solid endpoint patient
multipl co-morbid along sepsi area littl publish
clinic data good outcom european experi could go long way
beyond sepsi baxter expand crrt therapi remov lung
cytotoxin liver
medic deliveri baxter plan add sensor patient monitor
capabl cathet start impact busi
time-frame baxter file ip cathet incorpor puls oximetri
sensor measur blood satur expect manag discuss
compani move away core pump busi diagnost care
solut leverag baxter presenc hospit also medic
deliveri baxter launch sigma spectrum version pump
help sustain growth busi
baxter still view advanc surgeri potenti faster grow
busi despit recent perform compani loyal follow
surgeon across globe look expand product portfolio fill gap
either intern ie recothrom/prevaleak expect
manag focu drug side busi steer clear stapl
sutur etc domin
invest thesi valuat risk
baxter turnaround stori play better expect think there
still plenti room go sinc take januari ceo almeida
transform compani low-margin low-fcf busi one that
significantli under-lev gener signific vs
expand oper margin two year
baxter today top-lin growth busi see upsid potenti
opportun achiev margin expans next five year
driven mix upgrad gross margin improv exist busi
control oper spend that without put work underleverag
balanc sheet debt use drive earn power
either accret larg share buyback neither seem
reflect street model backdrop reiter overweight
rate stock
dec price target valu baxter equal blend
ev/ebitda ep compar large-cap med-tech peer
ev/ebitda ep assum baxter trade par
peer ev/ebitda appropri given lower leverag level vs
peer modest premium ep due potenti upsid capit
risk rate price
downsid risk includ manag inabl deliv margin
expans target misalloc balanc sheet potenti
reimburs price cut
baxter summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
